

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandra, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/575,112	07/11/2006	Michael Wilson	117581	9398	
23117 NIXON & VA	7590 08/08/200 NDERHYE, PC	EXAM	EXAMINER		
901 NORTH C	ELEBE ROAD, 11TH F	MACAULEY,	SHERIDAN R		
ARLINGTON	, VA 22203		ART UNIT	PAPER NUMBER	
			1651		
			MAIL DATE	DELIVERY MODE	
			08/08/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/575,112 WILSON ET AL. Office Action Summary Examiner Art Unit SHERIDAN R. MACAULEY 1651 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS.

WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Ethenisons of time may be available under the provisions of 37 CPR 11 136(a). In no event, however, may a rejet by be timely filed after SX (b) (MOVITHS from the making date of this communication. Figure 10 movement of the provision of the prov
Status
1) Responsive to communication(s) filed on <u>25 January 2007</u> .
2a) This action is FINAL . 2b) This action is non-final.
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.
Disposition of Claims
4)⊠ Claim(s) <u>1-30</u> is/are pending in the application.
4a) Of the above claim(s) is/are withdrawn from consideration.
5) Claim(s) is/are allowed.
6)☐ Claim(s) is/are rejected.
7) Claim(s) is/are objected to.
8) Claim(s) 1-30 are subject to restriction and/or election requirement.
Application Papers
9) The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d)
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

9)	The	spec	ifica	atio	n is	objected	to I	by the	Examiner
	_								. —

a) All b) Some * c) None of:

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Priority under 35 U.S.C. § 119

1.∟	Certified copies of the priority documents have been received.
2.	Certified copies of the priority documents have been received in Application No
3.	Copies of the certified copies of the priority documents have been received in this National Stage
	application from the International Bureau (PCT Pule 17.2(a))

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patient Drawing Review (PTO-948) 3) Information Disclosure-Statement(c) (PTO/SE/08) Paper No(s)Mail Date	4) Interview Summary (PTO-413) Paper No(s)Mail Date. 5. Notice of Informal Patent Attication 6) Other:	
I.C. Detectoral Vandament Office		_

Page 2

Application/Control Number: 10/575,112

Art Unit: 1651

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-12 and 28, drawn to a composition comprising a conjugate of a photosensitiser and a bacteriophage.

Group II, claim(s) 13-25 and 29, drawn to a method of killing bacteria.

Group III, claim(s) 26, 27 and 30, drawn to use of a bacteriophage.

- 2. The inventions listed as Groups I through III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The technical feature that is common to the groups is a composition comprising a conjugate of a photosensitiser and a bacteriophage. However, this feature was known in the art at the time of the invention, as evidenced by Hogset et al. (WO 02/44395; cited in IDS). The reference teaches a photosensitizing agent that may be attached to a bacteriophage (p. 20, line 21-p. 21, line 1). Therefore, there is not special technical feature common to the groups that makes a contribution over the prior art.
- 3. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Application/Control Number: 10/575,112

Art Unit: 1651

Election is required of the various species of bacteriophages recited in claims 2, 6 and 7. For example, applicant may elect a staphylococcal bacteriophage (recited in claim 1), phage 53 (recited in claim 6), or phage 75 (recited in claim 7).

Election is required of the various photosensitizers recited in claims 4 and 5. For example, applicant may elect fullerene (recited in claim 4), gilvocarcins (recited in claim 4), or SnCe6 (recited in claim 5).

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

4. The claims are deemed to correspond to the species listed above in the manner set forth above.

The following claim(s) are generic: Claim 1.

5. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The technical feature that is common to the inventions is a composition comprising a conjugate of a photosensitiser and a bacteriophage. However, this feature was known in the art at the time of the invention, as evidenced by Hogset et al. (WO 02/44395; cited in IDS). The reference teaches a photosensitizing agent that may be attached to a bacteriophage (p.

Application/Control Number: 10/575,112

Art Unit: 1651

20, line 21-p. 21, line 1). Therefore, there is not special technical feature common to the inventions that makes a contribution over the prior art.

6. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 8. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

 All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process Application/Control Number: 10/575,112

Art Unit: 1651

claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHERIDAN R. MACAULEY whose telephone number is (571)270-3056. The examiner can normally be reached on Mon-Thurs, 7:30AM-5:00PM EST, alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/575,112 Page 6

Art Unit: 1651

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Leon B Lankford/ Primary Examiner, Art Unit 1651

SRM